ChemoID

ChemoID is a predictive assay and functional diagnostic tool designed to personalize chemotherapy treatments for cancer patients. It works by testing the sensitivity of a patient’s cancer cells and cancer stem cells (CSCs) to various chemotherapy drugs, including FDA-approved drugs, targeted therapies, and drug combinations. The goal of ChemoID is to identify the most effective treatment options tailored to an individual patient, reducing the likelihood of ineffective therapies, minimizing side effects, and improving overall outcomes.

Key Features of ChemoID:

  1. Cancer Stem Cell Sensitivity Testing: It focuses on testing both cancer cells and CSCs, which are often more resistant to treatment and associated with tumor recurrence.
  2. Personalized Treatment: By evaluating how a patient’s specific cancer responds to different therapies, it provides actionable data for oncologists to design personalized treatment regimens.
  3. Companion Diagnostic: It is used alongside specific chemotherapy drugs to guide their selection and optimize effectiveness.
  4. Clinical Applications: ChemoID has been studied in various cancers, including glioblastoma multiforme (GBM), ovarian cancer, and other platinum-resistant cancers.

Benefits:

  • Helps reduce trial-and-error in chemotherapy.
  • Avoids unnecessary toxicity from ineffective drugs.
  • Improves the chances of selecting a successful treatment plan.
  • Provides a tool for precision medicine in oncology.

ChemoID has been investigated in clinical trials and is gaining attention for its potential to revolutionize cancer treatment strategies.

  1. Trial for Recurrent Glioblastoma Multiforme (GBM):
    • Focus: This study evaluated the use of ChemoID in patients with recurrent GBM, a highly aggressive and treatment-resistant brain tumor.
    • Outcome: The trial demonstrated that using ChemoID to select personalized chemotherapeutic regimens significantly improved patient outcomes, including progression-free survival (PFS) and overall survival (OS), compared to standard-of-care treatments.
    • Significance: This validation underscored ChemoID’s ability to predict effective treatments for highly resistant cancers like GBM.
  2. Trial for Recurrent Platinum – Resistant Ovarian Cancer:
    • Focus: This trial included patients with various recurrent or treatment-resistant solid tumors, such as ovarian cancer, and assessed the predictive accuracy of ChemoID for personalized treatment selection.
    • Outcome: Patients whose treatments were guided by ChemoID showed significantly better clinical outcomes (e.g., higher response rates and improved survival) compared to those receiving empiric chemotherapy without ChemoID guidance.
    • Significance: This trial confirmed the utility of ChemoID as a companion diagnostic for solid tumors, especially in cases of resistance to standard chemotherapy regimens.

Key Findings Across Both Trials:

  • ChemoID was effective in testing both bulk cancer cells and cancer stem cells (CSCs), which are known to drive tumor recurrence and drug resistance.
  • Patients receiving ChemoID-guided therapy had improved treatment responses, reduced toxicity, and better overall management of their cancers.

These trials validated the clinical relevance and potential of ChemoID as a functional precision medicine tool in oncology.

Patents

Patents Underlying the ChemoID Platform Technology

US 8,993,231 B2: Methods for Stem Cell Production and Therapy

US 9,316,632 B2: Methods of Screening Chemotherapeutic Agents and Treating Cancer

Click here for the ChemoID website.